• Kelun-Biotech flagged multiple readouts for its TROP2 ADC sacituzumab tirumotecan at the ESMO 2026 congress in Madrid.
• Data will be presented in late October, with several studies slated for oral sessions.
• Key disclosures include late-stage lung cancer results, positioned to inform first-line treatment choices or post-targeted therapy sequencing.
• A global pivotal endometrial cancer trial led by MSD is set for first presentation in a Presidential Symposium, raising visibility for the program.
• The slate also includes a Phase I update for SKB500, a B7-H3-targeted ADC, extending the company’s pipeline beyond TROP2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN70641) on October 13, 2026, and is solely responsible for the information contained therein.